Corticorelin
- Generic Name
- Corticorelin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 86784-80-7
- Unique Ingredient Identifier
- 305OE8862Y
- Background
Corticotropin-releasing factor is studied in the treatment of brain cancer. It is made naturally by the hypothalamus (a part of the brain) and can also be made in the laboratory. Human corticotropin-releasing factor may help reduce symptoms caused by edema (swelling) of the brain. It is a type of neurohormone, also called hCRF.
- Indication
Investigated for use/treatment in brain cancer and neurologic disorders.
- Associated Conditions
- -
- Associated Therapies
- -
Neurocrine Biosciences's Crinecerfont is Set to Transform the Congenital Adrenal
Neurocrine Biosciences' crinecerfont, targeting classic congenital adrenal hyperplasia (CAH), receives FDA Priority Review. If approved, it would be the first new CAH treatment in 70 years, offering a novel mechanism. CAH, caused by 21-hydroxylase gene mutations, affects hormone production in adrenal glands, with the US having the highest prevalence. Current treatments focus on managing symptoms, with EFMODY as the only approved drug in Europe. Emerging therapies like crinecerfont aim to normalize hormone levels and address the root cause of CAH.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath